Brian M. Shepler
Clinical Associate Professor of Pharmacy Practice
Director, Advanced Pharmacy Practice Experiences
PharmD, Purdue 1999
CLPH 872 (Therapeutics) - Chronic Kidney Disease; Hemodialysis, Peritoneal Dialysis, and other Renal Replacement Therapies; Acute Renal Failure and Drug Induced Nephrotoxicity
PHRM 403 (Integrated Lab) Instructor
PHRM 880 Coordinator for Advanced Pharmacy Practice Experiences
Ambulatory Care (Nephrology) Preceptor for an APPE rotation with the IU Health/Arnett Nephrology clinic focusing on the treatment of CKD and ESRD patients (i.e., anemia, hyperphosphatemia, secondary hyperparathyroidism, dialysis-related carnitine disorder, angio access infections, hyperkalemia, diurectic resistance, dyslipidemias, renal nutrition etc.)
Service and Engagement
Involved with all aspects of the experiential training program including orientation of new students and preceptors to the program, identification, development, and monitoring of APPE sites in concentrated areas across the state, preceptor evaluation, student rotation assignments etc.
CLPH 872 Therapeutics - CKD
PHRM 880 Amb Care Nephrology APPE
CLPH 866 Intro to APPE Program
Murawski M and Shepler B. Lilly Endowment Seed Grant 2009-2010. Initial development of patient completed questionnaire instruments designed to discern adverse drug reactions and adverse drug experiences in ambulatory patient populations. $49,892.
Administration and Committee Work
- Reviewer, The Journal of Continuing Education in the Health Professions
- External reviewer for promotion documents from peer institutions
- Reviewer, US Pharmacist
- Chair, Experiential Learning Advisory Council
- Member, North Central Indiana Area Health Education Council Steering Committee
- Member, Experiential Learning Academic Standards Committee
- Member, Admissions Committee
- Member, Non-Traditional Doctor of Pharmacy Advisory Committee
- Member, Assessment Committee
- Member, Task Force to Review the Readmissions Standards and Process
- Member, Electronic Literature Task Force
- Member, PharmD Curriculum Task Force
- Member, Therapeutics Sub-Committee
- Member, Patient Assessment Sub-Committee
- Member, Technical Standards Task Force
- Member, Search Committee for Manager of Alumni Relations
- Member, ACPE Self-Study Practice Facilities Committee
- Regional Faculty Coordinator
- STAR Advisor
- Chair, Search Committee for Director of Pharmacy Practice Labs
Shepler B, Hancock B, and Halley H. The New Pharmacy Trifecta: Preceptor Training Program. Presented at the Indiana Pharmacists Alliance Fall Meeting. French Lick, IN Sept 2011.
Kiersma M, Hess A, Shepler B, and Murawski M. Initial testing of instruments to discern adverse drug experiences in an ambulatory patient population. Presented at the American Pharmacists Association Annual Meeting and Exposition, Seattle WA, March 2011.
Coppol E, Shelly J, Cheng S, Kaakeh Y, and Shepler B. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. Presented at the ASHP Midyear Clinical Meeting, Anaheim, CA, Dec 2010.
Shepler B and Hancock B. Preceptor Development. Presented at the Indiana Pharmacists Alliance Fall Meeting, Indianapolis, IN, Sept 2010.
Kiersma M, Hess A, Villa K, Shepler B, and Murawski M. Prevalence of adverse drug effects and adverse drug reactions in the 200 most commonly prescribed drugs corrected for prescription volume. Presented at the International Conference on Pharmacoepidemiology and Therapeutic Risk Management, England, August 2010.
Mason M and Shepler B. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Presented at the ASHP Midyear Clinical Meeting in Las Vegas, NV, Dec 2009.
Shepler B, Nash C, Smith C, DiMarco A, Petty J, and Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012; 34(6): 1237-46. DOI 10.1016/j.clinthera.2012.04.026.
Gorbach C, Darbishire P, and Shepler B. Dialysis Concepts: A review for clinical pharmacists. US Pharm. 2011;36(6)67-74.(2 hour CE article)
Coppol E, Shelly J, Cheng S, Kaakeh Y, and Shepler B. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. Ann Pharmacother. 2011;45(2):241-7. (Author interview conducted for www.hemodialysis.com for this manuscript post publication)
Kiersma M, Chen A, Villa K, Shepler B, and Murawski M. Pharmaceutical systematic: Description and preliminary investigation of an alternative method for structuring drug information. Innovations in Pharmacy. 2011;2(1):1-9.
Chen AMH, Kiersma ME, Shepler BM, Murawski MM. Initial testing of instruments to discern adverse drug reactions and adverse drug experiences in an ambulatory patient population. Journal of the American Pharmacists Association 2011; 51(2):251
Mason M and Shepler B. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Pharmacotherapy. 2010;30(7):741-8.
Durham S, Miller R, Davis C, and Shepler B. Bisphosphonate nephrotoxicity risks and use in the chronic kidney disease population. US Pharm. 2010;35(3):Epub.
Darbishire P, Plake K, Nash C, and Shepler B. Active-learning laboratory session to teach the four M’s of diabetes care. Am J Pharm Ed. 2009;73(2):22.
Pai A and Shepler B. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009;29(5):554-61.
Byrnes C and Shepler B. Cinacalcet: A new treatment for secondary hyperparathyroidism in hemodialysis patients. Pharmacotherapy. 2005;25(5):709-16.
Darbishire P, Shepler B, and Sutton J. Differences among angiotensin receptor antagonists. US Pharm. 2004;10:HS19-25.